Rene Rodriguez-Gutierrez, MD; Nilay D. Shah, PhD; Victor M. Montori, MD, MSc
JAMA. 2015;314(18):1909-1910. doi:10.1001/jama.2015.13414
This Viewpoint anticipates widespread premature use of proprotein convertase subtilisin-kexin type 9 (PCSK-9) inhibitors in response to the challenges some patients experience taking statins and urges caution until trials and experience demonstrate the new drugs are safe.
S. Ben Freedman, MBBS, PhD; Nicole Lowres, BPhty, PhD
JAMA. 2015;314(18):1911-1912. doi:10.1001/jama.2015.9846
This Viewpoint proposes widespread screening for atrial fibrillation using accessible and inexpensive means as a public health intervention for preventing stroke.
Mary Cushman, MD, MSc; Mark A. Creager, MD
JAMA. 2015;314(18):1913-1914. doi:10.1001/jama.2015.15107
This Viewpoint discusses low public awareness about risk factors for and symptoms of venous thromboembolism and proposes quality initiatives that might improve recognition of venous thromboembolism and outcomes for patients.
Thijs M. H. Eijsvogels, PhD; Paul D. Thompson, MD
JAMA. 2015;314(18):1915-1916. doi:10.1001/jama.2015.10858
This Viewpoint discusses evidence that the beneficial effects of physical activity may vary depending on activity levels.
Sripal Bangalore, MD, MHA; David J. Maron, MD; Judith S. Hochman, MD
JAMA. 2015;314(18):1917-1918. doi:10.1001/jama.2015.11219
This Viewpoint summarizes controversies about the findings of clinical trials of revascularization for treatment of stable ischemic heart disease and argues for informing patients about the uncertainties.